<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781387</url>
  </required_header>
  <id_info>
    <org_study_id>19-0021</org_study_id>
    <secondary_id>75N93019C00056</secondary_id>
    <nct_id>NCT04781387</nct_id>
  </id_info>
  <brief_title>Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Comparator-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CRS3123 Compared With Oral Vancomycin in Adults With Clostridioides Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crestone, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Crestone, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to evaluate the primary objectives of safety and efficacy&#xD;
      (rate of clinical cure) of 2 dosages of CRS3123 (200 mg and 400 mg) administered orally (po)&#xD;
      twice daily (bid) and vancomycin administered 125 mg PO 4 times daily (qid) in adults &gt; or&#xD;
      equal to 18 years of age with a primary episode or first recurrence of CDI. The study will&#xD;
      investigate the plasma concentrations and HRQoL outcomes of CRS3123 and additional efficacy&#xD;
      endpoints as secondary objectives.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Anticipated">February 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Clinical Cure at Test of Cure (TOC) in the Intention to treat (ITT) population</measure>
    <time_frame>Day 12-14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Clinical cure at Test of Cure (TOC) in the Micro-Intent to Treat, Per Protocol and Microbiologically Evaluable populations</measure>
    <time_frame>Day 12-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of total relief of symptoms of Clostridioides difficile infection at Test of Cure (TOC) in the Micro-Intent to Treat, Per Protocol and Microbiologically Evaluable populations</measure>
    <time_frame>Day 12-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of diarrhea through Test of Cure (TOC) in the Micro-Intent to Treat, Per Protocol and Microbiologically Evaluable populations</measure>
    <time_frame>from date of randomization until the date of documented resolution, assessed up to Day 12-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of early recurrence of Clostridioides difficile infection through Follow up visit 3 (Day 40) in the Micro-ITT and ME populations</measure>
    <time_frame>Day 12 - Day 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of late recurrence of Clostridioides difficile infection (between Day 40 and Day 70) in the Micro-Intent to Treat and Microbiologically Evaluable populations</measure>
    <time_frame>Day 40 - Day 70</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recurrence of Clostridioides difficile infection through follow up visit 4 in the Micro-Intent to Treat and Microbiologic Evaluable populations</measure>
    <time_frame>Day 12 - Day 70</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of Clostridioides difficile infection through follow up visit 4 in the Micro-Intent to Treat, Per Protocol and Microbiologically Evaluable populations</measure>
    <time_frame>from Day 12 until the date of recurrence, assessed up to Day 70</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of global cure in the Micro-Intent to Treat, Per Protocol and Microbiologically evaluable populations</measure>
    <time_frame>Day 12 - Day 40</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Clostridioides Difficile Infection</condition>
  <arm_group>
    <arm_group_label>CRS3123 200 milligram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRS3123 200 milligram dose (400 mg/day) given orally at approximately 6-hour intervals for 10 days.&#xD;
Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRS3123 400 milligram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRS3123 400 milligram dose (800 mg/day) given orally at approximately 6-hour intervals for 10 days.&#xD;
Due to the difference in dosing schedules between CRS3123 (twice a day) and the standard of care vancomycin (four times a day) and appearance of study drugs used in the 3 Arms, placebo will be used to match the total number of capsules in each arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin 125 milligram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin 125 milligram dose (500 mg/day) given orally at approximately 6-hour intervals for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRS3123</intervention_name>
    <description>Study drug dosed at 200 mg PO BID (treatment arm A) or 400 mg PO BID (treatment arm B) for total of 10 days</description>
    <arm_group_label>CRS3123 200 milligram</arm_group_label>
    <arm_group_label>CRS3123 400 milligram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator</intervention_name>
    <description>Active comparator is administered 125 mg PO QID</description>
    <arm_group_label>Vancomycin 125 milligram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. More than or equal to 3 diarrheal stools/day in 24 hours prior to randomization and in&#xD;
             the judgment of the investigator that C difficile is the likely causative agent for&#xD;
             the diarrhea.&#xD;
&#xD;
          2. Stool positive for C. difficile GDH plus Toxin A and/or B&#xD;
&#xD;
          3. Participants with a primary episode or first recurrence of CDI are eligible&#xD;
&#xD;
          4. In the judgement of the investigator, the expectation that the participant will&#xD;
             survive with effective antibiotic therapy and appropriate supportive care for the&#xD;
             anticipated duration of the study&#xD;
&#xD;
          5. Participants may be either inpatient or outpatient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urs Ochsner, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Crestone, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy Ribble</last_name>
    <phone>303-668-2516</phone>
    <email>wribble@crestonepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katherine Johnson, DO, MSc</last_name>
    <phone>415-637-5220</phone>
    <email>kjohnson@crestonepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Advanced Clinical Research-Be Well</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sinikka Green, MD</last_name>
      <phone>737-204-1904</phone>
      <email>sgreen@velocityclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Colleen Jacobsen</last_name>
      <phone>737-204-1904</phone>
      <email>sjacobsen@velocityclinical.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDI</keyword>
  <keyword>Cdiff Infection</keyword>
  <keyword>Clostridiodes difficile infection</keyword>
  <keyword>Cdiff</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

